NCT02717039 Pharmacogenomics of Heparin-Induced Thrombocytopenia
| NCT ID | NCT02717039 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Arizona |
| Condition | Heparin-induced Thrombocytopenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 125 participants |
| Start Date | 2016-03 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 125 participants in total. It began in 2016-03 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Ability to give informed consent * Have undergone testing for heparin/PF4 antibody with or without SRA testing for HIT * Have received treatment with unfractionated heparin or low molecular weight heparin (enoxaparin, dalteparin, tinzaparin) prior to antibody or SRA testing Exclusion Criteria: * Less than 18 years of age * Pregnancy * Hemoglobin less than 9 mg/dL (for larger 5 ounce blood draw) * Known Human Immunodeficiency Virus (HIV) infection * Inability to give informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02717039 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heparin-induced Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02717039 currently recruiting?
Yes, NCT02717039 is actively recruiting participants. Contact the research team at karnes@pharmacy.arizona.edu for enrollment information.
Where is the NCT02717039 trial being conducted?
This trial is being conducted at Tucson, United States.
Who is sponsoring the NCT02717039 clinical trial?
NCT02717039 is sponsored by University of Arizona. The trial plans to enroll 125 participants.